Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cullinan Management (CGEM)
NASDAQ:CGEM
Cullinan Management (CGEM) Stock Price & Analysis
128 Followers
CGEM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.64 - $30.19
Previous Close$16.59
Volume1.92M
Average Volume (3M)989.79K
Market Cap
$956.15M
Enterprise Value$526.31M
Total Cash (Recent Filing)$433.01M
Total Debt (Recent Filing)$3.17M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 08, 2024EPS Estimate
-$0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.14
Shares Outstanding57,634,234
10 Day Avg. Volume1,254,540
30 Day Avg. Volume989,795
Standard Deviation0.17
R-Squared0.00026
Alpha0.00182
Financial Highlights & Ratios
Price to Book (P/B)2.14
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue657.89
Enterprise Value/Gross Profit1.05K
Enterprise Value/Ebitda-3.96
Forecast
1Y Price Target
$33.00Price Target Upside72.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Cullinan Management News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsInitial data from the Ph 2b REZILIENT1 trial of small molecule TKI zipalertinib shows an encouraging 39% ORR and 94% DCR in EGFR ex20ins NSCLC patients who failed at least prior chemotherapy and amivantamab.
Regulatory Approval PotentialZipalertinib has the potential for accelerated approval in EGFR ex20ins NSCLC based on the ongoing Phase 3 trial outcomes.
Safety ProfileZipalertinib has shown a favorable safety profile with a 19.4% Gr3 TRAE rate and a 5% discontinuation rate.
Bears Say
Clinical TrialsCullinan is discontinuing enrollment in the CLN-978 B-NHL study to focus on autoimmune diseases, following mixed results from the study.
Drug DevelopmentThe projected development timeline for CLN-619 is extended due to a considerable number of avenues for later-stage development.
Safety ConcernsDue to amivantamab's safety profile, chemotherapy is still used in the 1L setting despite amivantamab's significant benefits.
---
Ownership Overview
54.12% Insiders
8.87% Mutual Funds
12.36% Other Institutional Investors
24.66% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CGEM FAQ
What was Cullinan Management’s price range in the past 12 months?
Cullinan Management lowest stock price was $7.64 and its highest was $30.19 in the past 12 months.
What is Cullinan Management’s market cap?
Currently, no data Available
When is Cullinan Management’s upcoming earnings report date?
Cullinan Management’s upcoming earnings report date is Aug 08, 2024 which is in 22 days.
How were Cullinan Management’s earnings last quarter?
Cullinan Management released its earnings results on May 15, 2024. The company reported -$0.86 earnings per share for the quarter, beating the consensus estimate of -$0.99 by $0.13.
Is Cullinan Management overvalued?
According to Wall Street analysts Cullinan Management’s price is currently Undervalued.
Does Cullinan Management pay dividends?
Cullinan Management does not currently pay dividends.
What is Cullinan Management’s EPS estimate?
Cullinan Management’s EPS estimate is -$0.73.
How many shares outstanding does Cullinan Management have?
Cullinan Management has 57,634,235 shares outstanding.
What happened to Cullinan Management’s price movement after its last earnings report?
Cullinan Management reported an EPS of -$0.86 in its last earnings report, beating expectations of -$0.99. Following the earnings report the stock price went down -10.891%.
Which hedge fund is a major shareholder of Cullinan Management?
Among the largest hedge funds holding Cullinan Management’s share is Deerfield Management Company, LP. It holds Cullinan Management’s shares valued at 19M.
---
Cullinan Management Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (72.96% Upside)
$33.00 (72.96% Upside)
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.55%
12-Months-Change
Fundamentals
Return on Equity
-29.05%
Trailing 12-Months
Asset Growth
-12.73%
Trailing 12-Months
Company Description
Cullinan Management
Cullinan Management Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
---
CGEM Stock 12 Month Forecast
Average Price Target
$33.00
▲(72.96% Upside)
Technical Analysis
Best Analysts Covering CGEM
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+45.68%
assigned a buy rating 2 months ago
Copying Kaveri Pohlman's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +45.68% per trade.
---